Skip to main content

Table 1 Metabolic and cardiac phenotype in AT treated mice

From: Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ‘SIRT1 and PGC-1α’

 

WT

WT + AT

WT + AT + CR

db/db

db/db + AT

db/db + AT + CR

IVS; d (mm)

0.8 ± 0.1

0.9 ± 0.1

0.8 ± 0.2

0.9 ± 0.1

1.1 ± 0.1#

1 ± 0.1&

IVS; s (mm)

1.2 ± 0.1

1.2 ± 0.2

1.4 ± 0.5

1.4 ± 0.2*

1.6 ± 0.2#

1.5 ± 0.3*

LVPW; d (mm)

0.9 ± 0.1

1 ± 0.1

0.8 ± 0.1^

0.9 ± 0.1

1.1 ± 0.2#

0.9 ± 0.2&

LVPW; s (mm)

1.2 ± 0.1

1.1 ± 0.1

1.3 ± 0.1

1.2 ± 0.2

1.5 ± 0.3#

1.2 ± 0.3&

LVEDD (mm)

3.6 ± 0.7

4.2 ± 0.4*

3.5 ± 0.5^

3.9 ± 0.2

3.5 ± 0.05#

4.1 ± 0.4&

LVESD (mm)

2.9 ± 0.2

3.3 ± 0.6

1.93 ± 0.8^

2.6 ± 0.3*

2.4 ± 0.6*

2.5 ± 0.5

FS (%)

33 ± 14

21 ± 7*

46 ± 14^

34 ± 7

30 ± 7

41 ± 10&

Body weight (g)

26 ± 3

25± 2

19 ±  1*

41 ± 10*

40 ± 5*

33 ± 7&

Heart weight (mg)

115 ± 2

148 ± 3*

97 ± 2^

117 ± 2

163 ± 3#

139 ± 2&

Systolic blood pressure (mmHg)

95 ± 21

134 ± 29*

117 ± 13

99 ± 30

148 ± 15#

114 ± 11&

Glucose (mg/dL)

137 ± 44

111 ± 41

107 ± 43

617 ± 93*

658 ± 107*

531 ± 127&

AST (U/L)

62 ± 25

60 ± 11

60 ± 18

127 ± 53*

226 ± 149#

99 ± 21&

ALT (U/L)

126 ± 42

130 ± 30

127 ± 56

182 ± 134

281 ± 176*

117 ± 32&

Cholesterol (mg/dL)

79 ± 24

101 ± 22*

8 ± 70^

112 ± 21*

199 ± 91#

118 ± 25&

Triglycerides (mg/dL)

124 ± 57

125 ± 25

22 ± 82^

185 ± 66*

208 ± 75*

127 ± 35&

  1. Values are mean±SD
  2. IVS;d intra ventricular septum in diastole, IVS;s intra ventricular septum in systole, LVPW;d left ventricle posterior wall in diastole, LVPW;s left ventricle posterior wall in systole, LVESD left ventricle end systolic dimension, LVEDD left ventricle end diastolic dimension, FS fractional shortening, AST aspartate aminotransferase, ALT alanine aminotransferase
  3. *p < 0.05 vs. WT, ^p<0.05 vs.WT+AT, #p<0.05 vs. db/db, &p<0.05 vs. db/db+ AT